Total Payments
$62,099
2024 Payments
$2,870
Companies
11
Transactions
70
Medicare Patients
1,902
Medicare Billing
$235,162
Payment Breakdown by Category
Consulting$55,864 (90.0%)
Travel$4,056 (6.5%)
Food & Beverage$2,049 (3.3%)
Education$130.35 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $55,864 | 17 | 90.0% |
| Travel and Lodging | $4,056 | 18 | 6.5% |
| Food and Beverage | $2,049 | 31 | 3.3% |
| Education | $130.35 | 4 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Mallinckrodt Hospital Products Inc. | $33,187 | 14 | $0 (2023) |
| Mallinckrodt Enterprises LLC | $18,394 | 25 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $4,400 | 2 | $0 (2024) |
| Veloxis Pharmaceuticals, Inc. | $3,946 | 18 | $0 (2023) |
| Amgen Inc. | $1,471 | 2 | $0 (2022) |
| Alexion Pharmaceuticals, Inc. | $176.83 | 3 | $0 (2024) |
| Aurinia Pharma U.S., Inc. | $138.48 | 2 | $0 (2022) |
| GlaxoSmithKline, LLC. | $125.00 | 1 | $0 (2021) |
| Otsuka America Pharmaceutical, Inc. | $117.61 | 1 | $0 (2017) |
| GENZYME CORPORATION | $100.81 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,870 | 2 | Novartis Pharmaceuticals Corporation ($2,750) |
| 2023 | $1,782 | 5 | NOVARTIS PHARMACEUTICALS CORPORATION ($1,650) |
| 2022 | $10,331 | 8 | Mallinckrodt Hospital Products Inc. ($8,706) |
| 2021 | $12,600 | 6 | Mallinckrodt Hospital Products Inc. ($12,455) |
| 2020 | $11,996 | 5 | Mallinckrodt Hospital Products Inc. ($11,996) |
| 2019 | $9,590 | 21 | Mallinckrodt Enterprises LLC ($9,478) |
| 2018 | $12,713 | 21 | Mallinckrodt LLC ($8,916) |
| 2017 | $218.42 | 2 | Otsuka America Pharmaceutical, Inc. ($117.61) |
All Payment Transactions
70 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/27/2024 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $2,750.00 | General |
| 06/01/2024 | Alexion Pharmaceuticals, Inc. | SOLIRIS (Biological) | Food and Beverage | In-kind items and services | $119.70 | General |
| Category: Rare Disease | ||||||
| 12/05/2023 | Veloxis Pharmaceuticals, Inc. | ENVARSUS (Drug) | Food and Beverage | In-kind items and services | $37.33 | General |
| Category: TRANSPLANTATION | ||||||
| 09/28/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Consulting Fee | Cash or cash equivalent | $1,650.00 | General |
| 09/12/2023 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $22.31 | General |
| Category: Rare Disease | ||||||
| 09/06/2023 | Mallinckrodt Hospital Products Inc. | TERLIVAZ (Drug) | Food and Beverage | In-kind items and services | $29.69 | General |
| Category: CRITICAL CARE | ||||||
| 08/02/2023 | Takeda Pharmaceuticals U.S.A., Inc. | LIVTENCITY (Drug) | Food and Beverage | In-kind items and services | $43.07 | General |
| Category: IMMUNOLOGY | ||||||
| 12/07/2022 | Mallinckrodt Hospital Products Inc. | TERLIVAZ (Drug) | Consulting Fee | Cash or cash equivalent | $3,710.00 | General |
| Category: CRITICAL CARE | ||||||
| 12/07/2022 | Amgen Inc. | Tavneos (Drug) | Consulting Fee | Cash or cash equivalent | $1,425.00 | General |
| Category: Not Applicable | ||||||
| 12/07/2022 | Mallinckrodt Hospital Products Inc. | TERLIVAZ (Drug) | Food and Beverage | In-kind items and services | $85.00 | General |
| Category: CRITICAL CARE | ||||||
| 11/04/2022 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $45.97 | General |
| Category: Inflammation | ||||||
| 06/29/2022 | Mallinckrodt Hospital Products Inc. | — | Consulting Fee | Cash or cash equivalent | $4,770.00 | General |
| 06/04/2022 | Mallinckrodt Hospital Products Inc. | — | Food and Beverage | In-kind items and services | $141.37 | General |
| 05/26/2022 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $34.82 | General |
| Category: Rare Disease | ||||||
| 05/12/2022 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $118.79 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 11/16/2021 | Mallinckrodt Hospital Products Inc. | — | Consulting Fee | Cash or cash equivalent | $3,445.00 | General |
| 09/10/2021 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Education | In-kind items and services | $19.69 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 04/28/2021 | Mallinckrodt Hospital Products Inc. | — | Consulting Fee | Cash or cash equivalent | $2,650.00 | General |
| 03/30/2021 | Mallinckrodt Hospital Products Inc. | — | Consulting Fee | Cash or cash equivalent | $2,650.00 | General |
| 03/03/2021 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: IMMUNOLOGY | ||||||
| 03/01/2021 | Mallinckrodt Hospital Products Inc. | — | Consulting Fee | Cash or cash equivalent | $3,710.00 | General |
| 12/07/2020 | Mallinckrodt Hospital Products Inc. | — | Consulting Fee | Cash or cash equivalent | $2,250.00 | General |
| 09/30/2020 | Mallinckrodt Hospital Products Inc. | — | Consulting Fee | Cash or cash equivalent | $2,475.00 | General |
| 08/29/2020 | Mallinckrodt Hospital Products Inc. | — | Consulting Fee | Cash or cash equivalent | $3,150.00 | General |
| 05/15/2020 | Mallinckrodt Hospital Products Inc. | — | Consulting Fee | Cash or cash equivalent | $3,825.00 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 429 | 636 | $302,747 | $49,083 |
| 2022 | 9 | 371 | 672 | $320,158 | $50,900 |
| 2021 | 10 | 478 | 849 | $97,923 | $65,165 |
| 2020 | 13 | 624 | 989 | $131,634 | $70,016 |
Total Patients
1,902
Total Services
3,146
Medicare Billing
$235,162
Procedure Codes
40
All Medicare Procedures & Services
40 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 121 | 183 | $82,350 | $17,579 | 21.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 51 | 128 | $57,856 | $12,253 | 21.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 46 | 110 | $34,540 | $6,907 | 20.0% |
| 93784 | Ambulatory blood pressure monitoring, 1 day or longer, with recording, scanning analysis, interpretation, and report | Office | 2023 | 120 | 120 | $84,480 | $3,851 | 4.6% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 38 | 39 | $18,993 | $3,514 | 18.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 28 | 31 | $9,176 | $1,995 | 21.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 13 | 13 | $7,852 | $1,716 | 21.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 12 | 12 | $7,500 | $1,268 | 16.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 72 | 220 | $99,440 | $17,682 | 17.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 108 | 144 | $64,800 | $14,119 | 21.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 53 | 126 | $39,564 | $7,124 | 18.0% |
| 90945 | Dialysis procedure including 1 evaluation | Facility | 2022 | 13 | 54 | $43,254 | $3,720 | 8.6% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 30 | 32 | $15,584 | $2,590 | 16.6% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 19 | 20 | $12,000 | $2,169 | 18.1% |
| 93784 | Ambulatory blood pressure monitoring, 1 day or longer, with recording, scanning analysis, interpretation, and report | Office | 2022 | 54 | 54 | $38,016 | $1,806 | 4.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 11 | 11 | $6,644 | $1,490 | 22.4% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 11 | 11 | $856.00 | $199.59 | 23.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 88 | 294 | $33,949 | $24,328 | 71.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 107 | 154 | $23,817 | $15,008 | 63.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 61 | 128 | $10,448 | $7,269 | 69.6% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 47 | 49 | $5,967 | $4,108 | 68.8% |
| 90945 | Dialysis procedure including one evaluation | Facility | 2021 | 16 | 61 | $7,428 | $4,100 | 55.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 28 | 30 | $7,122 | $3,947 | 55.4% |
| 93784 | Ambulatory blood pressure monitoring, 24 hours or longer, with recording, scanning analysis, interpretation, and report | Office | 2021 | 83 | 83 | $4,440 | $2,743 | 61.8% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 19 | 20 | $2,739 | $2,214 | 80.8% |
About Dr. Hani Wadei, MD
Dr. Hani Wadei, MD is a Nephrology healthcare provider based in Jacksonville, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/14/2005. The National Provider Identifier (NPI) number assigned to this provider is 1851372148.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Hani Wadei, MD has received a total of $62,099 in payments from pharmaceutical and medical device companies, with $2,870 received in 2024. These payments were reported across 70 transactions from 11 companies. The most common payment nature is "Consulting Fee" ($55,864).
As a Medicare-enrolled provider, Wadei has provided services to 1,902 Medicare beneficiaries, totaling 3,146 services with total Medicare billing of $235,162. Data is available for 4 years (2020–2023), covering 40 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Jacksonville, FL
- Active Since 11/14/2005
- Last Updated 12/18/2020
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1851372148
Products in Payments
- TERLIVAZ (Drug) $3,825
- Envarsus XR (SP) (Drug) $3,797
- Tavneos (Drug) $1,425
- LUPKYNIS (Drug) $138.48
- BENLYSTA (Biological) $125.00
- SOLIRIS (Biological) $119.70
- SAMSCA (Drug) $117.61
- Envarsus (Drug) $111.66
- THYMOGLOBULIN (Drug) $100.81
- ULTOMIRIS (Biological) $57.13
- TAVNEOS (Drug) $45.97
- LIVTENCITY (Drug) $43.07
- ENVARSUS (Drug) $37.33
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Jacksonville
Dr. Craig Shapiro, M.d, M.D
Nephrology — Payments: $56,961
Nephrology $56,961
Jeremy Carlson
Nephrology — Payments: $56,912
Nephrology $56,912
Dr. Deborah Price, M.d, M.D
Nephrology — Payments: $11,451
Nephrology $11,451
Dr. Koithara Varkey Thomas, M.d, M.D
Nephrology — Payments: $8,020
Nephrology $8,020
Nabeel Aslam, Md, MD
Nephrology — Payments: $6,975
Nephrology $6,975
Dr. Michael Brumback, M.d, M.D
Nephrology — Payments: $6,414
Nephrology $6,414